Advanced Cancer Clinical Trial
Official title:
Histology-Independent Study of the Multikinase Inhibitor Lucitanib (E3810) in Patients With Advanced Cancer and Fibroblast Growth Factor Receptor (FGFR), Vascular Endothelial Growth Factor Receptors (VEGFR), or Platelet Derived Growth Factor Receptor (PDGFR) Pathway Aberrations
NCT number | NCT02747797 |
Other study ID # | 141506 |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | April 2017 |
Est. completion date | April 2022 |
Verified date | July 2018 |
Source | University of California, San Diego |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Lucitanib is an oral multi kinase inhibitor designed to block the action of certain molecules
called "angiogenic factors" that may cause tumors to grow. These factors are called vascular
endothelial growth factor (VEGF), platelet derived growth factor receptor (PDGFR) and
fibroblast growth factor (FGF). Lucitanib is experimental and not approved by the FDA for the
treatment of cancer.
The purpose of this study is to look at the effects of lucitanib in cancer patients whose
cancers harbor aberrations in FGFR, VEGFR, PDGFR or other markers predicted to be sensitive
to lucitanib. This study will also look for biomarkers in samples of blood and tumor tissue
to identify patients most likely to respond to lucitanib. Biomarkers are substances such as
genetic material (DNA and RNA) and proteins found in blood and tumor tissue that might show
if a cancer patient will respond or not respond to a drug.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | April 2022 |
Est. primary completion date | April 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following: - Subject is intolerant of standard therapy - Malignancy is refractory to standard therapy - Malignancy relapsed after standard therapy - Malignancy for which there is no standard therapy that improves survival by at least 3 months. - Subjects must have evaluable tumor(s) with documented alteration(s) in potential lucitanib related biomarker(s) VEGFR, FGFR, PDGFR. - Laboratory function within specified parameters: - Adequate bone marrow function: absolute neutrophil count = 1,500/mL; hemoglobin = 8.5 g/dL, platelets = 75,000/mL. - Adequate liver function: transaminases (AST/ALT) and alkaline phosphatase = 3 (= 5 X ULN in the setting of liver metastasis) x ULN; bilirubin = 1.5 x ULN. - Adequate renal function: creatinine clearance = 40 mL/min (Cockcroft Gault). - Adequate blood coagulation: international normalized ratio (INR) = 2.3. - Serum amylase and lipase = 1.5 x ULN. - Adequately controlled blood pressure (BP): BP = 150/90 mm Hg. Use of > 2 antihypertensive agents at enrollment is not allowed. - Adequate performance status: Eastern Cooperative Oncology Group (ECOG) 0-2 - Subjects must be off other anti-tumor agents for at least 5 half lives of the agent or 4 weeks from the last day of treatment, whichever is shorter. Endocrine therapies (e.g., for breast or prostate cancer) and anti-Her2 therapies (for example, trastuzumab, pertuzumab, or lapatinib) are allowed to continue while on this study. Bisphosphonates or denosumab are allowed for subjects with bone metastasis. - Subjects may not be receiving any other experimental agents or agents that are not FDA approved. Exclusion Criteria: - Pregnant or lactating women. - Uncontrolled hypertension (defined as SBP = 140 mmHg and/or DBP = 90 mmHg with optimized antihypertensive therapy) - Subjects who have not recovered from toxicities as a result of prior anticancer therapy, except alopecia and infertility. Recovery is defined as < Grade 2 severity per Common Terminology Criteria for Adverse Events Version 4.3. - Significant cardiovascular impairment: history of CHF greater than New York Heart Association (NYHA) Class II, unstable angina, MI or stroke within 6 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment. - Uncontrolled hypothyroidism defined as serum TSH higher than 5 mIU/mL while receiving appropriate thyroid hormone therapy. - Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR monitoring, e.g., warfarin or similar agents. Treatment with LMWH and factor X inhibitors that do not require INR monitoring is permitted. Anti-platelet agents are prohibited throughout the study. - Current treatment with any prohibited medications associated with prolongation of QT interval. - Received strong inhibitors of CYP2C8 or CYP3A4 or strong inducers of CYP3A4 = 7 days prior to first dose of lucitanib or have on-going requirements for these medications. - Received bevacizumab < 3 months prior to first dose of lucitanib. - Major surgery (not including placement of central lines) within 3 weeks prior to study or planned surgery during the course of this study. - Subjects with breast or lung cancer who are eligible for other clinical trials of lucitanib open at their institution are not eligible for this trial. |
Country | Name | City | State |
---|---|---|---|
United States | UC San Diego Moores Cancer Center | La Jolla | California |
Lead Sponsor | Collaborator |
---|---|
Teresa Helsten, MD | Clovis Oncology, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response rates to lucitanib in subjects with advanced cancers harboring aberrations targeted by lucitanib. | 28-day cycle | ||
Secondary | Clinical Benefit rates (complete response (CR), partial response (PR), or stable disease (SD) = 6 months) in the study population. | Clinical Benefit will be defined as SD = 6 cycles and PR/CR of any duration. | through study completion, up tp 3 years | |
Secondary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Toxicities will be described according to the NCI-CTCAE Version 4.3. Unacceptable toxicity is defined as any clinically significant Grade 3 or 4 toxicity including expected toxicities definitely, probably, or possibly related to the study medication that are not amenable to dose reduction | 28-day cycle | |
Secondary | Correlation between response rates and specific molecular tumor profile (type of FGF/FGFR or other aberration) in a descriptive fashion | 28-day cycle |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 |